ReviewCancer science2012
Elimination of asbestos use and asbestos-related diseases: an unfinished story.
Review in Cancer science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 45 citations in OpenAlex.
- Asbestos and cancer in Latin America and the Caribbean: we may have won some battles, but definitely not the war.Journal of public health research · 2021Article
- Recent progress and perspectives on the mechanisms underlying Asbestos toxicity.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- Prevention of Asbestos Exposure in Latin America within a Global Public Health Perspective.Annals of global health · 2019Review
- Asbestos-related diseases in mineworkers: a clinicopathological study.ERJ open research · 2017Article
- Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.Disease markers · 2017Article
- Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis.Canadian respiratory journal · 2017Article
- Recent Scientific Evidence Regarding Asbestos Use and Health Consequences of Asbestos Exposure.Current environmental health reports · 2016Review
- Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.Environmental health and preventive medicine · 2015Article
- Improved Method for Analysis of Airborne Asbestos Fibers Using Phase Contrast Microscopy and FTIR Spectrometry.Tanaffos · 2014Article
- Malignant pleural mesothelioma: an epidemiological perspective.Annals of cardiothoracic surgery · 2012Article
- Current Asbestos Exposure and Future Need for Palliative Care in India.Indian journal of palliative careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asbestos is a proven human carcinogen. Asbestos-related diseases (ARDs) typically comprise lung cancer, malignant mesothelioma, asbestosis, pleural plaques, thickening and effusion. International organizations, notably the World Health Organization and the International Labour Organization, have repeatedly declared the need to eliminate ARDs, and have called on countries to stop using asbestos. However, the relevant national-level indicators (e.g., incidence/mortality rates and per capita asbestos use, as well as their interrelationships) indicate that ARDs are increasing and asbestos use is continuing in the world. Lessons learned by industrialized countries in terms of policy and science have led to a growing number of countries adopting bans. In contrast, industrializing countries are faced with a myriad of forces prompting them to continue using asbestos. Full-scale international cooperation will thus be needed, with industrialized countries sharing their experiences and technologies to enable industrializing countries to make smooth transitions to banned states and achieve the goal of eliminating ARDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.